Esperion Therapeutics’ (ESPR) Buy Rating Reaffirmed at HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $16.00 target price on the biopharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on ESPR. StockNews.com downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 17th. Bank of America downgraded shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and lowered their price objective for the stock from $2.90 to $2.50 in a report on Thursday, June 20th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Esperion Therapeutics in a report on Friday, June 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Esperion Therapeutics currently has an average rating of “Hold” and a consensus target price of $8.83.

Esperion Therapeutics Stock Performance

Shares of NASDAQ ESPR traded down $0.14 during midday trading on Monday, reaching $1.88. The company’s stock had a trading volume of 6,428,173 shares, compared to its average volume of 7,200,272. The business’s 50 day moving average price is $2.41 and its two-hundred day moving average price is $2.37. The company has a market cap of $356.18 million, a P/E ratio of -1.95 and a beta of 1.02. Esperion Therapeutics has a fifty-two week low of $0.70 and a fifty-two week high of $3.40.

Institutional Investors Weigh In On Esperion Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BOKF NA bought a new stake in Esperion Therapeutics in the 2nd quarter worth approximately $26,000. Herbst Group LLC purchased a new position in shares of Esperion Therapeutics in the 1st quarter worth $28,000. Private Portfolio Partners LLC purchased a new stake in shares of Esperion Therapeutics during the 4th quarter valued at about $30,000. CVI Holdings LLC purchased a new position in shares of Esperion Therapeutics during the first quarter valued at approximately $37,000. Finally, Simplicity Wealth LLC bought a new stake in shares of Esperion Therapeutics during the first quarter worth $44,000. 47.39% of the stock is owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.